1,5-anhydroglucitol Blood Test More Accurate than HbA1c and Glucose for Predicting Mortality COVID-19 Patients with and without Diabetes

This week, Precision Diabetes, Inc. presented data demonstrating that the 1,5-anhydroglucitol blood test (GlycoMark®) is more accurate than commonly used diabetes tests in predicting mortality in hospitalized COVID-19 patients with and without diabetes. The study, “1,5-anhydroglucitol is an Independent Predictor of Mortality in Patients with COVID-19,” was presented at the American Heart Association (AHA) 2021 Scientific Sessions conference.

The study, conducted at Sinai Hospital in Baltimore, Md., showed that the GlycoMark® test had 76% mortality accuracy (AUC) compared to the accuracy for HbA1c and fasting glucose of 51% and 60%, respectively. The accuracy of GlycoMark was higher in patients without diabetes (79%) than in patients with diabetes (73%). An algorithm, which included age, BMI, and GlycoMark had an accuracy for prediction of mortality of 89%.

“We were pleased to find that the GlycoMark test identified mortality with high accuracy in COVID-19 patients,” says Paul Gurbel, MD, a cardiologist at the The LifeBridge Health Cardiovascular Institute and lead investigator of the trial. “GlycoMark may have utility in triaging COVID-19 patients in the hospital setting at higher risk of severity and mortality. This may be especially important in COVID-19 non-diabetic patients who may develop new-onset diabetes, which brings higher risks of severe disease and death.”

This study follows a previously reported study presented as a late-breaking abstract at the 2021 American Diabetes Association (ADA) Scientific Sessions, which showed that GlycoMark was an effective marker of stress hyperglycemia and severity in COVID-19 patients, particularly in patients without diabetes. The study was conducted at Hospital Universitario Cruces in Bilbao, Spain.

You may also like

  • Attention Type 1 Diabetes Researchers

    Request for Proposals (RFP) to Promote Research and Solutions for People with Type 1 Diabetes to Safely Incorporate Exercise into Their Daily Lives The Leona M. and Harry B. Helmsley Charitable Trust’s Type 1 Diabetes Program is launching an initiative to support novel, real-world solutions to help people with type 1 diabetes exercise safely and…

  • Bone Fragility in Diabetes: New Research Focuses on Diabetic Bone Disease

    People with diabetes have an increased risk of fractures, which is often underdiagnosed and impacts their mobility as well as their mortality. A new array of treatments and assessments — novel therapeutics, senolytics, revamped prescribing protocols, and more — are needed to better concentrate on diabetic bone disease. An emerging complication of both type 1…